|
If the slide opens in your browser, select File -> Save As to save it.)
Copyright restrictions may apply. Please see our Conditions of Use.
Fig. 1. Serum potassium in 14 haemodialysed patients included in the study (black dots) and in 21 controls who declined the study (grey dots). Lines represent non-parametric regression lines. Patients in the spironolactone group received no treatment during weeks 1–2 (run-in) and 7–8 (wash-out), 12.5 mg after each haemodialysis session during weeks 3–4, and 25 mg during weeks 5–6. Control patients received no spironolactone throughout.
|